Candel Therapeutics, Inc. reveals strategy for advancing prostate cancer and glioma programs
Candel Therapeutics, Inc. announced its strategy for advancing oncology programs, with CEO Paul Peter Tak presenting at the Stifel 2026 Virtual Targeted Oncology Forum. The company is focusing on its clinical pipeline, specifically in prostate cancer, non-small cell lung cancer (NSCLC), and recurrent glioma. This presentation offers an early look at Candel's strategy and research developments in the oncology sector, highlighting their commitment to patient-driven innovation and regulatory standards.
MAY 16·Traders Union→
Candel Therapeutics Inc presents new extended follow-up phase 3 data for CAN-2409 in prostate cancer
Candel Therapeutics, Inc. has released new extended follow-up data from its phase 3 trial for CAN-2409 in localized prostate cancer. The results, presented at the #AUA26 meeting, provide further insight into the efficacy and durability of the investigational immunotherapy. This comes alongside other recent company recognition, such as the CEO emphasizing patient engagement and the Chief Regulatory Officer being named among RAPSorg 50 for 50.
MAY 16·Stock Titan▲
Phase 3 prostate cancer data highlight Candel Therapeutics (NASDAQ: CADL)
Candel Therapeutics (NASDAQ: CADL) reported positive extended follow-up results from its pivotal Phase 3 trial of aglatimagene besadenovec (CAN-2409) for intermediate- to high-risk localized prostate cancer. The immunotherapy, combined with standard radiotherapy, demonstrated a 39% improvement in prostate cancer-specific disease-free survival in the overall population and 41% in the intermediate-risk subgroup, with significant hazard ratios. The treatment was well-tolerated, and Candel plans to submit a Biologics License Application (BLA) in Q4 2026, positioning CAN-2409 as a potential new therapy in over 20 years.
